Pure Global

A Study of Duvelisib in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL) - Trial NCT03372057

Access comprehensive clinical trial information for NCT03372057 through Pure Global AI's free database. This Phase 2 trial is sponsored by SecuraBio and is currently Active, not recruiting. The study focuses on Peripheral T-cell Lymphoma. Target enrollment is 120 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT03372057
Phase 2
Active, not recruiting
drug
Trial Details
ClinicalTrials.gov โ€ข NCT03372057
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
A Study of Duvelisib in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL)
A Multi-Center, Phase 2, Open-label, Parallel Cohort Study of Efficacy and Safety of Duvelisib in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL)

Study Focus

Duvelisib

Interventional

drug

Sponsor & Location

SecuraBio

Duarte,Irvine,Los Angeles,Atlanta,Chicago,Louisville,Baltimore,Boston,Saint Louis,New York,Rochester,Stony Brook,Charlotte,Charlotte,Durham,Columbia,Toledo,Pittsburgh,Dallas,Halle,Dresden,Bergamo,Bolo, Germany,Italy,United Kingdom,United States of America

Timeline & Enrollment

Phase 2

Feb 22, 2018

Dec 01, 2024

120 participants

Primary Outcome

Objective response rate (ORR)

Summary

This is a multi-center, parallel cohort, open-label, Phase 2 study of duvelisib, an oral dual
 inhibitor of PI3K-ฮด,ฮณ, in patients with relapsed or refractory Peripheral T cell Lymphoma
 (PTCL).

ICD-10 Classifications

Peripheral T-cell lymphoma, not elsewhere classified
Cutaneous T-cell lymphoma, unspecified
Mature T/NK-cell lymphomas
Angioimmunoblastic T-cell lymphoma
Other mature T/NK-cell lymphomas

Data Source

ClinicalTrials.gov

NCT03372057

Non-Device Trial